Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Using CRISPR technology to identify genes preferentially essential for multiple myeloma cells

Constantine Mitsiades • 29 Sep 2023
IMS 2023
Multiple Myeloma

Constantine Mitsiades, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses a study which used CRISPR technology to characterize and understand which genes are essential for multiple myeloma cells. Dr Mitsiades highlights the value of this work and explains how this information may be used to identify new therapeutic targets. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Constantine Mitsiades

1:40
Highlights from IMS 2023: integrating multi-omic technologies & understanding resistance
Constantine Mitsiades • 29 Sep 2023
8:43
Highlights from the IMW 2021 meeting
Constantine Mitsiades • 11 Sep 2021
4:35
Cereblon pathway-mediated IMiD resistance in multiple myeloma
Constantine Mitsiades • 7 Sep 2018
13:23
Novel therapeutics in multiple myeloma
Christoph Driessen et al. • 18 Oct 2017

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals